Matthew Fowler | Authors


JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS

February 09, 2021

A phase 1 study is the first to demonstrate that JSP191 is safe and effective in older patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

HRQoL Maintained With Added Pembrolizumab in Esophageal Cancer

January 16, 2021

In patients with esophageal cancer, chemotherapy with or without added pembrolizumab led to similar health-related quality of life results over 18 weeks, according to findings from the phase 3 KEYNOTE-590 study.

Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma

December 07, 2020

The combination of daratumumab with lenalidomide, bortezomib, and dexamethasone followed by maintenance therapy with daratumumab and lenalidomide improved response rates and depth of response rates with statistically significance as treatment of patients with transplant-eligible newly diagnosed multiple myeloma.